EVOKE PHARMA INC's ticker is EVOK and the CUSIP is 30049G104. A total of 20 filers reported holding EVOKE PHARMA INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $3,499,000 | -16.8% | 1,410,946 | 0.0% | 0.39% | -18.4% |
| Q3 2018 | $4,205,000 | +19.2% | 1,410,946 | 0.0% | 0.48% | -0.6% |
| Q2 2018 | $3,527,000 | +330.6% | 1,410,946 | +258.2% | 0.49% | +291.9% |
| Q1 2018 | $819,000 | -52.9% | 393,852 | -48.8% | 0.12% | -39.2% |
| Q4 2017 | $1,738,000 | -8.9% | 769,149 | +34.7% | 0.20% | -25.0% |
| Q3 2017 | $1,907,000 | +49.0% | 571,022 | +14.2% | 0.27% | +25.3% |
| Q2 2017 | $1,280,000 | -17.4% | 500,000 | 0.0% | 0.22% | -28.4% |
| Q1 2017 | $1,550,000 | – | 500,000 | – | 0.30% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 242,500 | $1,962,000 | 1.69% |
| SOPHROSYNE CAPITAL LLC | 49,000 | $397,000 | 0.40% |
| LMR Partners LLP | 23,882 | $187,000 | 0.02% |
| GEODE CAPITAL MANAGEMENT, LLC | 10,276 | $80,000 | 0.00% |
| BlackRock Investment Management, LLC | 489 | $4,000 | 0.00% |
| MORGAN STANLEY | 500 | $4,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 84 | $1,000 | 0.00% |
| VANGUARD GROUP INC | 48,394 | $378,000 | 0.00% |
| UBS AG | 727 | $6,000 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 33,500 | $271,000 | 0.00% |